HSRProj will be retired on September 14, 2021, no updates will be made to HSRProj after this date.
Detailed information about this transition can be found on the June 3, 2021 Technical Bulletin post.
If you have questions or suggestions, please contact NLM Customer Service.
Information about ongoing health services research and public health projects
|Comparative effectiveness of breast cancer screening and diagnostic evaluation by extent of breast density|
|Investigator (PI):||Miglioretti, Diana|
|Performing Organization (PO):||
(Current): University of California, Davis Health System, School of Medicine, Department of Public Health Sciences, Division of Biostatistics / (530) 752-2793
|Supporting Agency (SA):||Patient-Centered Outcomes Research Institute (PCORI)|
|Record Source/Award ID:||PCORI/PCS-1504-30370|
|Funding:||Total Award Amount: $8,128,405|
|Award Information:||PCORI: More information and project results (when completed)|
|Abstract:||Breast density, one of the strongest risk factors for breast cancer, impacts breast cancer detection on mammography. Yet, there is limited evidence to guide questions women and their physicians face on how best to incorporate breast density into clinical care. This study will answer the following questions with the goal of personalizing breast cancer screening and preoperative work-up decisions: What is the best way to screen women with or without dense breasts? In the United States, 27.6 million women of screening age have dense breasts, and laws in almost half the states require notification so women may consider supplemental screening. Digital breast tomosynthesis, magnetic resonance imaging (MRI), and ultrasound are diffusing rapidly into community practice with insufficient evidence to guide screening decisions. Should breast MRI be used before surgical decisions in women with newly diagnosed breast cancer? Preoperative MRI, used for evaluation of a new cancer diagnosis, is increasingly controversial due to conflicting evidence of benefit overall or for subgroups of women. While MRI detects additional disease, its impact on patient-centered clinical and patient-reported outcomes has not been adequately addressed, overall or by breast density. The outcomes we hope to achieve are to (1) enable women to understand the effectiveness of different supplemental screening options (tomosynthesis, ultrasound, or MRI) by extent of breast density; and (2) allow patients with a breast cancer diagnosis to understand the risks and benefits of preoperative MRI by extent of breast density. Ultimately, we aim to inform screening guidelines and ensure that decisions about preoperative work-up are aligned with a woman's individual characteristics and preferences. Women we surveyed were concerned with how breast density should be factored into screening and clinical decisions to detect or treat breast cancer. We have incorporated questions and outcomes important to women throughout the study. For example, we will assess screening failures because 76 percent of women surveyed felt it was extremely important that the exam not miss the presence of breast cancer. We will also assess second cancer events, because it is important to women to have good estimates of subsequent disease risk when making diagnostic and surgical decisions. Our research team includes four patient partners, two with dense breasts and two breast cancer survivors. Representatives from the American Cancer Society, American College of Radiology, US Preventive Services Task Force, Are You Dense?, D.E.N.S.E., BlueShield of California, Advocate Healthcare, and clinical providers serve as stakeholders. These perspectives, along with those from stakeholders, patient partners, focus groups, and key informant interviews, shaped our research aims and approach and will help ensure the project's success.|
|Record History:||('2020: Project extended to 2022.',)|